中智药业发布中期业绩，股东应占利润878.3万元，同比下降89.5%

Core Viewpoint - Zhongzhi Pharmaceutical (03737) reported a revenue of 880 million RMB for the six months ending June 30, 2025, representing a year-on-year decline of 19.1% [1] - The profit attributable to the parent company was 8.783 million RMB, down 89.5% year-on-year, with basic earnings per share of 0.010 RMB [1] Financial Performance - Revenue for the period was 880 million RMB, showing a significant decrease of 19.1% compared to the previous year [1] - Profit attributable to the parent company decreased to 8.783 million RMB, reflecting a sharp decline of 89.5% year-on-year [1] - Basic earnings per share were reported at 0.010 RMB [1]